Epstein Barr Virus Volume 2

One Herpes Virus: Many Diseases

  • Christian Münz

Part of the Current Topics in Microbiology and Immunology book series (CT MICROBIOLOGY, volume 391)

Table of contents

  1. Front Matter
    Pages i-vi
  2. EBV Latency

    1. Front Matter
      Pages 1-1
    2. Lori Frappier
      Pages 3-34
    3. Bettina Kempkes, Paul D. Ling
      Pages 35-59
    4. Arnd Kieser, Kai R. Sterz
      Pages 119-149
    5. Osman Cen, Richard Longnecker
      Pages 151-180
    6. Rebecca L. Skalsky, Bryan R. Cullen
      Pages 181-217
  3. Lytic EBV Infection

    1. Front Matter
      Pages 219-219
    2. Liudmila S. Chesnokova, Ru Jiang, Lindsey M. Hutt-Fletcher
      Pages 221-235
    3. Jessica McKenzie, Ayman El-Guindy
      Pages 237-261
  4. Immune Responses to EBV

    1. Front Matter
      Pages 263-263
    2. Anna Lünemann, Martin Rowe, David Nadal
      Pages 265-287
    3. Andrew D. Hislop, Graham S. Taylor
      Pages 325-353
    4. Maaike E. Ressing, Michiel van Gent, Anna M. Gram, Marjolein J. G. Hooykaas, Sytse J. Piersma, Emmanuel J. H. J. Wiertz
      Pages 355-381
  5. Animal Models of EBV Infection

    1. Front Matter
      Pages 383-383
  6. Therapy of EBV Associated Diseases

    1. Front Matter
      Pages 425-425
    2. Stephen Gottschalk, Cliona M. Rooney
      Pages 427-454
    3. Corey Smith, Rajiv Khanna
      Pages 455-473
    4. Jennifer Kanakry, Richard Ambinder
      Pages 475-499
  7. Back Matter
    Pages 501-505

About this book


Epstein Barr virus (EBV) was discovered as the first human tumor virus around 50 years ago. Since its discovery in Burkitt’s lymphoma it has been associated with various other malignancies, infectious mononucleosis and even autoimmune diseases. The two book volumes on EBV summarize the first 50 years of research on this tumor virus, starting with historical perspectives on discovery, oncogenicity and immune control, reviewing the role that the virus plays in the various associated diseases and concluding with a discussion on how the immune system keeps persistent EBV infection under control in healthy EBV carriers and can be used to treat EBV associated diseases. The respective 32 chapters are written by international experts from three continents for health care providers, biomedical researchers and patients that are affected by EBV. The assembled knowledge should help to understand EBV associated diseases better and to develop EBV specific vaccination in the near future.


cell-mediated immune control human tumor virus immunotherapies lymphomas and carcinomas persistent infection

Editors and affiliations

  • Christian Münz
    • 1
  1. 1.Institute of Experimental ImmunologyUniversity of ZürichZürichSwitzerland

Bibliographic information

Industry Sectors
Health & Hospitals
Oncology & Hematology
Consumer Packaged Goods